

Referencias

- Bahamondes L, Lavin P, Ojeda G, et al. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem. *Contraception* 1997;55:307-10.
- Bassol S, Garza-Flores J. Review of ovulation return upon discontinuation of once-a-month injectable contraceptives. *Contraception* 1994;49:441-53.
- Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns: a review. *Contraception* 1988;38:129-56.
- Benagiano G, Primiero FM, Bastianelli C, et al. Comparative clinical evaluation of the effect on carbohydrate and lipid metabolism of two norethisterone-containing hormonal contraceptives: Mesigyna and TriNovum. *Contraception* 1997;55:295-300.
- Bracken MB. Oral contraceptives and congenital malformations in offspring. A review and meta-analysis of the prospective studies. *Obstet Gynecol* 1990;76:552-57.
- Coutinho EM, Spinola P, Barbosa I, et al. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. *Contraception* 1997;55:175-81.
- Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. *J Pediatr* 1996;129:671-76.
- Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. *J Reprod Med* 1996;41(Suppl 5):428-34.
- Cundy T, Cornish J, Evans MC, et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. *Br Med J* 1994;308:247-48.
- Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot-medroxyprogesterone acetate for contraception. *Br Med J* 1991;303:13-16.
- Cuong DT, My Hyong NT. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women. *Contraception* 1996;54:169-79.
- de Abood M, de Castillo Z, Guerrero F, et al. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. *Contraception* 1997;56:313-16.

- De Ceulaer K, Hayes R, Gruber C, et al. Medroxyprogesterone acetate and homozygous sickle-cell disease. *Lancet* 1982;2:229-31.
- Dennerstein GJ. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. *J Reprod Med* 1986;31:801-803.
- Dorflinger LJ. Medical contraindications and issues for consideration in the use of once-a-month injectable contraceptives. *Contraception* 1994;49:455-68.
- Fraser IS. Vaginal bleeding patterns in women using once-a-month injectable contraceptives. *Contraception* 1994;49:399-419.
- Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot-medroxyprogesterone acetate. *Med J Austral* 1981;1(Spec Suppl):3-20.
- Garza-Flores J. Cyclofem/Cyclo-Provera: emerging countries' perspective. *Int J Gynecol Obstet* 1998;62(Suppl 1):S31-S36.
- Gray RH. Reduced risk of pelvic inflammatory disease with injectable contraceptives (letter) *Lancet* 1985;1:1046.
- Gray RH, Pardthaisong T. In utero exposure to steroid contraceptives and survival during infancy. *Am J Epidemiol* 1991;134:804-11.
- Gunning JE, Moyer D. The effect of medroxyprogesterone acetate on endometriosis in the human female. *Fertil Steril* 1967;18:759-74.
- Hall PE, Bahamondes L, Díaz J, et al. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia and Peru. *Contraception* 1997;56:353-59.
- Hall PE, WHO Task Force on Research on Introduction and Transfer of Technologies for Fertility Regulation. The introduction of Cyclofem into national family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. *Contraception* 1994;49:489-507.
- Hatcher RA, Trussell J, Stewart F, et al. *Contraceptive Technology*. New York: Ardent Media, Inc., 1998.
- IMAP statement on injectable contraception. *IPPF Med Bull*, 1999;33(2).
- Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. *J Reprod Med* 1996;41(Suppl 5):419-27.
- Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. *Int J Fertil Womens Med* 1998;43:73-83.

Kesserü EV, Aydinlik S, Etchepareborda JJ. Multicentred, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. *Contraception* 1994;50:329-37.

Kistner RW. The treatment of endometriosis by inducing pseudopregnancy with ovarian hormones: a report of fifty-eight cases. *Fertil Steril* 1959;10:539-56.

Koetsawang S. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation. *Contraception* 1994;49:387-98.

Koetsawang, S. The effects of contraceptive methods on quality and quantity of breastmilk. *Int J Gynecol Obstet* 1987;25(Suppl):115-27.

Jimenez J, Ochoa M, Soler MP, et al. Long-term follow-up of children breastfed by mothers receiving depo-medroxyprogesterone acetate. *Contraception* 1984;30:523-33.

Lande RE. New era for injectables. *Population Reports* 1995;Series K(5).

Lei Z-W, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depot-medroxyprogesterone acetate for contraception. *Contraception* 1996;53:357-61.

Lumbiganon P. Depo-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary. *Contraception* 1994;49:203-12.

Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin-only contraceptives. *Contraception* 1995;51:149-53.

Mattson RH, Cramer JA, Caldwell BV, et al. Treatment of seizures with medroxyprogesterone acetate: preliminary report. *Neurology* 1984;34:1255-58.

Naessen T, Olsson S-E, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in pre-menopausal women. *Contraception* 1995;52:35-39.

OMS. *Mejorando el acceso a la calidad de atención en planificación familiar: Criterios de elegibilidad médica para el uso de los anticonceptivos*. Ginebra: OMS, 1997.

Pardthaisong T. Return of fertility after use of the injectable contraceptive Depo-Provera: updated data analysis. *J Biosocial Sci* 1984;16:23-24.

Pardthaisong T, Gray R. In utero exposure to steroid contraceptives and outcome of pregnancy. *Am J Epidemiol* 1991;134:795-803.

Pardthaisong T, Yencht C, Gray R. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. *Contraception* 1992;45:313-24.

Paul C, Skegg DCG, Spears GFS. Depot-medroxyprogesterone (Depo-Provera) and risk of breast cancer. *Br Med J* 1989;299:759-62.

Population Council. Focus on the Philippine DMPA reintroduction program: continuing users vs. drop-outs. *Population Council Research News: Asia and Near East Operations Research and Technical Assistance Project* 1996;Apr(7):1-2.

Rosenblatt KA, Thomas DB. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. *Int J Cancer* 1991;49:182-85.

Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and side effects. *Contraception* 1995;51:167-83.

Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. *Contraception* 1995;51:185-92.

Scholes D, LaCroix AZ, Ott SM, et al. Bone mineral density in women using depot-medroxyprogesterone acetate for contraception. *Obstet Gynecol* 1999;93:233-38.

Schwallie PC, Assenzo JR. The effect of depot-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. *Contraception* 1974;10:181-202.

Skegg DCG, Noonan EA, Paul C, et al. Depot-medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand studies. *J Am Med Assoc* 1995;273:799-804.

Simpson JL, Phillips OP. Spermicides, hormonal contraception and congenital malformations. *Adv Contracept* 1990;6:141-67.

Stanford JL, Thomas DB. Depot-medroxyprogesterone acetate and risk of epithelial ovarian cancer. *Int J Cancer* 1991;49:191-95.

Technical Guidance Working Group. *Recomendaciones para la actualización de prácticas seleccionadas en el uso de anticonceptivos. Resultados de una Reunión Técnica. Volumen I.* Washington: Agencia de los Estados Unidos para el Desarrollo Internacional, 1994.

Technical Guidance/Competence Working Group. *Recomendaciones para la actualización de prácticas seleccionadas en el uso de anticonceptivos. Resultados de una Reunión Técnica. Volumen II.* Washington: Agencia de los Estados Unidos para el Desarrollo Internacional, 1997.

Technical Guidance/Competence Working Group, World Health Organization, Division of Family Health. Family planning methods: new guidance. *Population Reports* 1996;44:1-48.

Thomas DB, Noonan EA. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. *Lancet* 1991;338:833-38.

Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. *Int J Cancer* 1991;49:186-90.

Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. *Contraception* 1992;45:299-312.

Thomas DB, Ye Z, Ray RM, et al. Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). *Contraception* 1995;51:25-31.

Tieng P. Return to fertility after use of the injectable contraceptive Depo-Provera: updated analysis. *Oklahoma City: Second Asian Regional Workshop on Injectable Contraceptives*. 1992:30-38.

Topozada MK. Existing once-a-month combined injectable contraceptives. *Contraception* 1994;49:293-301.

Topozada M, Onsy FA, Fares E, et al. The protective influence of progesterone-only contraception against vaginal moniliasis. *Contraception* 1979;20:99-103.

United Nations, Department for Economic and Social Information and Policy Analysis. *Levels and Trends of Contraceptive Use as Assessed in 1994*. New York: United Nations, 1996.

Westhoff C. Depot medroxyprogesterone acetate contraception: metabolic parameters and mood changes. *J Reprod Med* 1996;41(5 Suppl):401-06.

WHO. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. *Bull WHO* 1993;70:677-89.

WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. *Contraception* 1998;57:315-24.

WHO Task Force for Epidemiological Research on Reproductive Health. Progestogen-only contraceptives during lactation: I. Infant growth. *Contraception* 1994;50:35-53.

WHO Task Force for Epidemiological Research on Reproductive Health. Progestogen-only contraceptives during lactation: II. Infant development. *Contraception* 1994;50:55-68.

WHO Task Force on Intrauterine Devices. PID associated with fertility-regulating agents. *Contraception* 1984;30:1-21.

WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: I. Contraceptive efficacy and side effects. *Contraception* 1986;34:223-35.

WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. *Contraception* 1987;35:591-610.

WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given one-a-month by intramuscular injection: I. Contraceptive efficacy and side effects. *Contraception* 1988;37:1-20.

WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given one-a-month by intramuscular injection: II. Comparison of bleeding patterns. *Contraception* 1989;40:531-51.

WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on glucose metabolism and liver function. *Contraception* 1998;57:71-81.

WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate; final report. *Contraception* 1983;28:1-20.